Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer

Annals of Oncology

Volumn 26, Issue 9, 2015, Pages 1838-1845

  Lee, Richard T ^a   Ramchandran, K ^b   Sanft, T ^c   von Roenn, J ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Stanford Medicine Children s Health   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Best supportive care; Cancer clinical trials; Palliative care; Supportive care

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANXIOLYTIC AGENT; CORTICOSTEROID; OPIATE;

BEST SUPPORTIVE CARE; BLOOD TRANSFUSION; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COLORECTAL CANCER; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; NUTRITIONAL COUNSELING; PANCREAS CANCER; PATIENT CARE; PATIENT REFERRAL; PLEURODESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SOCIAL ASPECT; SOCIAL WORK; SPIRITUAL CARE; STANDARDIZATION; STOMACH CANCER; SUPPORTIVE CARE; SYSTEMATIC REVIEW; THORACOCENTESIS; WORLD HEALTH ORGANIZATION; ANALGESIA; CLINICAL TRIAL (TOPIC); NEOPLASMS; PALLIATIVE THERAPY; PROCEDURES; QUALITY OF LIFE; SOCIAL SUPPORT;

CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PAIN MANAGEMENT; PALLIATIVE CARE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SOCIAL SUPPORT;

EID: 84941614160     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv207     Document Type: Review

References (111)

1. Sanft TB, Von Roenn JH. Palliative care across the continuum of cancer care. J Natl Compr Canc Netw 2009; 7: 481-487.
2. World Health Organization. National Cancer Control Programmes: Policies and Managerial Guidelines, 2nd edition. Geneva: World Health Organization, 2002.
3. Pelayo A, Westeel V, Cortés-Jofré M, Bonfill Cosp X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2013; 11: CD001990.
4. Burdett S, Stephens R, Stewart L et al. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26: 4617-4625.
5. de Kort SJ, Willemse PHB, Habraken JM et al. Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: a review of randomized controlled clinical trials. Eur J Cancer 2006; 42: 835-845.
6. Joly F, Vardy J, Pintilie M, Tannock IF. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 2007; 18: 1935-1942.
7. Stewart LA, Pignon JP. Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
8. Cullen M. 'Best supportive care' has had its day. Lancet Oncol 2001; 2: 173-175.
9. Zafar SY, Currow D, Abernethy AP. Defining best supportive care. J Clin Oncol 2008; 26: 5139-5140.
10. Sanchez-Munoz A, Perez-Ruiz E, Saez MI et al. Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. Clin Transl Oncol 2011; 13: 426-429.
11. Cherny NI, Abernethy AP, Strasser F et al. Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. J Clin Oncol 2009; 27: 5476-5486.
12. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742.
13. Cherny N. Best supportive care: a euphemism for no care or a standard of good care? Semin Oncol 2011; 38: 351-357.
14. Institute of Medicine (U.S.). Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Graham R. Clinical practice guidelines we can trust. Washington, DC: National Academies Press, 2011.
15. Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1990; 804: 1-75.
16. Ferris FD, Bruera E, Cherny N et al. Palliative cancer care a decade later: accomplishments, the need, next steps-from the American Society of Clinical Oncology. J Clin Oncol 2009; 27: 3052-3058.
17. Levy MH, Back A, Benedetti C et al. NCCN clinical practice guidelines in oncology: palliative care. J Natl Compr Canc Netw 2009; 7: 436-473.
18. Ferrell B, Connor SR, Cordes A et al. The national agenda for quality palliative care: the National Consensus Project and the National Quality Forum. J Pain Symptom Manage 2007; 33: 737-744.
19. National Institute of Clinical Excellence. Guidance on Cancer Services: Improving Supportive and Palliative Care for Adults with Cancer. 2004; https://www.nice.org.uk/guidance/csgsp (27 September 2014, date last accessed).
20. Hui D, Mori M, Parsons HA et al. The lack of standard definitions in the supportive and palliative oncology literature. J Pain Symptom Manage 2012; 43: 582-592.
21. Amadori S, Suciu S, Selleslag D et al. Randomized trial of two schedules of lowdose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol 2010; 149: 376-382.
22. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000; 83: 447-453.
23. Barni S, Lissoni P, Cazzaniga M et al. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 1995; 52: 243-245.
24. Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumcontaining regimen in patients with advanced transitional cell carcinoma of the urothelial tract.[Erratum appears in J Clin Oncol. 2010 Jan 1;28(1):182 Note: Winquist, Eric [added]]. J Clin Oncol 2009; 27: 4454-4461.
25. Brodowicz T, Krzakowski M, Zwitter M et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-163.
26. Buccheri GF, Ferrigno D, Curcio A et al. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 1989; 63: 428-432.
27. Butts C, Maksymiuk A, Goss G et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011; 137: 1337-1342.
28. Cartei G, Cartei F, Cantone A et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 794-800.
29. Cascinu S, Del Ferro E, Catalano G. A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 1995; 71: 97-101.
30. Cellerino R, Tummarello D, Guidi F et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991; 9: 1453-1461.
31. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
32. Ciuleanu TE, Pavlovsky AV, Bodoky G et al. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer 2009; 45: 1589-1596.
33. Cullen MH, Billingham LJ, Woodroffe CM et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-3194.
34. Cunningham D, Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 1999; 26: 6-12.
35. De Marinis F, Rinaldi M, Ardizzoni A et al. The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Italian Lung Cancer Task Force. Tumori 1999; 85: 177-182.
36. Dollinger MM, Lautenschlaeger C, Lesske J et al. Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. BMC Cancer [on-line] 2010; http://www.biomedcentral.com/1471-2407/10/457 (5 May 2013, date last accessed).
37. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
38. Ganz PA, Figlin RA, Haskell CM et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 1989; 63: 1271-1278.
39. Garcia B, Neninger E, de la Torre A et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008; 14: 840-846.
40. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168.
41. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
42. Goss G, Ferry D, Wierzbicki R et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009; 27: 2253-2260.
43. Harousseau JL, Martinelli G, Jedrzejczak WW et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009; 114: 1166-1173.
44. Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Eur J Cancer 1998; 34: 1036-1044.
45. Hofmann MA, Hauschild A, Mohr P et al. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial. Melanoma Res 2011; 21: 516-523.
46. Huguier M, Barrier A, Valinas R et al. Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer. Hepatogastroenterology 2001; 48: 875-878.
47. Jassem J, Ramlau R, Santoro A et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26: 1698-1704.
48. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
49. Kaasa S, Lund E, Thorud E et al. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 1991; 67: 2443-2447.
50. Kang JH, Lee SI, Lim do H et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513-1518.
51. Kantarjian H, Issa J-PJ, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. [see comment]. Cancer 2006; 106: 1794-1803.
52. Karamouzis MV, Ioannidis G, Rigatos G. Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study. Eur J Cancer Care 2007; 16: 433-438.
53. Leung WT, Shiu WC, Pang JC et al. Combined chemotherapy and radiotherapy versus best supportive care in the treatment of inoperable non-small-cell lung cancer. Oncology 1992; 49: 321-326.
54. Lissoni P, Barni S, Ardizzoia A et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 1992; 49: 336-339.
55. Lissoni P, Barni S, Ardizzoia A et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 1994; 73: 699-701.
56. Lissoni P, Barni S, Fossati V et al. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. Support Care Cancer 1995; 3: 194-197.
57. Lissoni P, Brivio F, Fumagalli L et al. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res 2008; 28: 1377-1381.
58. Lubbert M, Suciu S, Baila L et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29: 1987-1996.
59. Machiels JP, Subramanian S, Ruzsa A et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011; 12: 333-343.
60. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
61. Muers MF, Rudd RM, O'Brien ME et al. BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax 2004; 59: 144-148.
62. Muers MF, Stephens RJ, Fisher P et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-1694.
63. Mulens V, De La Torre A, Marinello P et al. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: results from a controlled study in metastatic breast cancer patients. Hum Vaccin 2010; 6: 736-744.
64. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
65. O'Brien ME, Ciuleanu TE, Tsekov H et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-5447.
66. Olweny CL, Borok M, Gudza I et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer 2005; 113: 632-639.
67. Parikh PM, Vaid A, Advani SH et al. Randomized, double-blind, placebocontrolled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 2011; 29: 4129-4136.
68. Paz-Ares L, de Marinis F, Dediu M et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-smallcell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247-255.
69. Pelzer U, Schwaner I, Stieler J et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47: 1676-1681.
70. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
71. Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1074-1080.
72. Rao S, Cunningham D, de Gramont A et al. Phase III double-blind placebocontrolled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004; 22: 3950-3957.
73. Rapp E, Pater JL, Willan A et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-641.
74. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
75. Reichardt P, Blay JY, Gelderblom H et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012; 23: 1680-1687.
76. Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized nonsmall cell lung cancer (NSCLC). Lung Cancer 2000; 27: 145-157.
77. Scheithauer W, Rosen H, Kornek GV et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-755.
78. Sharma A, Dwary AD, Mohanti BK et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28: 4581-4586.
79. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
80. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
81. Spiro SG, Rudd RM, Souhami RL et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004; 59: 828-836.
82. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
83. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24: 17-24.
84. Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306-2314.
85. Tsavaris N, Tentas K, Tzivras M et al. Combined epirubicin, 5-fluorouracil and folinic acid vs no treatment for patients with advanced pancreatic cancer: a prospective comparative study. J Chemother 1998; 10: 331-337.
86. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
87. Vinageras EN, De La Torre A, Rodriguez MO et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 1452-1458.
88. Windle R, Bell PR, Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987; 74: 569-572.
89. Woods RL, Williams CJ, Levi J et al. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990; 61: 608-611.
90. Xia Y, Qiu Y, Li J et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol 2010; 17: 3137-3144.
91. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
92. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91: 66-72.
93. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998; 352: 17-20.
94. Zafar SY, Currow DC, Daugherty CK, Abernethy AP. Standards for palliative care delivery in oncology settings. Cancer J 2010; 16: 436-443.
95. Jack B, Boland A, Dickson R et al. Best supportive care in lung cancer trials is inadequately described: a systematic review. Eur J Cancer Care (Engl) 2010; 19: 293-301.
96. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977; 196: 129-136.
97. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1, 000 patients. Support Care Cancer 2000; 8: 175-179.
98. Kirkova J, Walsh D, Rybicki L et al. Symptom severity and distress in advanced cancer. Palliat Med 2010; 24: 330-339.
99. Lidstone V, Butters E, Seed PT et al. Symptoms and concerns amongst cancer outpatients: identifying the need for specialist palliative care. Palliat Med 2003; 17: 588-595.
100. Teunissen SC, Wesker W, Kruitwagen C et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007; 34: 94-104.
101. Bakitas M, Lyons KD, Hegel MT et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009; 302: 741-749.
102. Zimmermann C, Swami N, Krzyzanowska M et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014; 383: 1721-1730.
103. Follwell M, Burman D, Le LW et al. Phase II study of an outpatient palliative care intervention in patients with metastatic cancer. J Clin Oncol 2009; 27: 206-213.
104. Meyers FJ, Linder J, Beckett L et al. Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care. J Pain Symptom Manage 2004; 28: 548-556.
105. Glare PA, Semple D, Stabler SM, Saltz LB. Palliative care in the outpatient oncology setting: evaluation of a practical set of referral criteria. J Oncol Pract 2011; 7: 366-370.
106. Spiegel D, Butler LD, Giese-Davis J et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Cancer 2007; 110: 1130-1138.
107. Andersen BL, Yang HC, Farrar WB et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer 2008; 113: 3450-3458.
108. Goodwin PJ, Leszcz M, Ennis M et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001; 345: 1719-1726.
109. Ikeda A, Kawachi I, Iso H et al. Social support and cancer incidence and mortality: the JPHC study cohort II. Cancer Causes Control 2013; 24: 847-860.
110. Zafar SY, Currow DC, Cherny N et al. Consensus-based standards for best supportive care in clinical trials in advanced cancer. Lancet Oncol 2012; 13: e77-e82.
111. Naeim A, Aapro M, Subbarao R, Balducci L. Supportive care considerations for older adults with cancer. J Clin Oncol 2014; 32: 2627-2634.